Azrieli Neurodevelopmental Centre, Centre for Addiction and Mental Health (CAMH), Ontario, Canada; Department of Psychiatry, University of Toronto, Ontario, Canada; ICES, Ontario, Canada.
Department of Psychiatry, University of Toronto, Ontario, Canada; ICES, Ontario, Canada; Unity Health, Ontario, Canada.
Disabil Health J. 2022 Jan;15(1):101174. doi: 10.1016/j.dhjo.2021.101174. Epub 2021 Jul 26.
Across and within countries there is a need to understand how the COVID-19 pandemic has impacted populations of individuals with intellectual and developmental disabilities (IDD).
Rates of COVID-19 positivity for adults with IDD, including Down syndrome, relative to adults without IDD in Ontario, Canada were compared. Health profiles and case-based rates of hospitalizations, intensive care unit admissions, and mortality within 30 days of testing positively were compared for those with IDD, including Down syndrome, versus those without IDD.
This retrospective cohort study linked health administrative databases using unique encoded identifiers to describe population-level COVID-19 positivity, related hospital use and mortality from January 15, 2020 to January 10, 2021. Incidence rate ratios (RR) and 95% confidence intervals were calculated.
Relative to adults without IDD, COVID-19 positivity rates were 1.28 times higher for adults with IDD and 1.42 times higher for adults with Down syndrome. Compared to adults without IDD, adults with IDD were more than twice as likely to be hospitalized following COVID-19 (RR:2.21 (95%CI: 1.93,2.54)) and to die (RR:2.23 (95%CI: 1.86,2.67). These RRs were greater for adults under 65. For adults with Down syndrome, mortality rates were 6.59 (95%CI: 4.51,9.62) times higher than those without IDD.
In Ontario, Canada, hospitalization and mortality rates associated with COVID-19 are higher for adults with IDD than other adults. These findings should inform vaccination strategies that often prioritize older adults in the general population resulting in people with IDD, who are often in younger age groups, being overlooked.
在国家之间和内部,需要了解 COVID-19 大流行对智障和发育障碍(ID)人群的影响。
比较加拿大安大略省成年智障人士(包括唐氏综合征患者)与非智障人士 COVID-19 阳性率。比较智障人士(包括唐氏综合征患者)和非智障人士在检测呈阳性后 30 天内住院、重症监护病房入院和死亡的病例基础率。
本回顾性队列研究使用唯一编码标识符链接健康管理数据库,以描述 2020 年 1 月 15 日至 2021 年 1 月 10 日期间的人口 COVID-19 阳性率、相关住院使用和死亡率。计算发病率比(RR)和 95%置信区间。
与非智障成年人相比,智障成年人 COVID-19 阳性率高 1.28 倍,唐氏综合征成年人高 1.42 倍。与非智障成年人相比,智障成年人 COVID-19 后住院的可能性是其两倍多(RR:2.21(95%CI:1.93,2.54)),死亡的可能性也是其两倍多(RR:2.23(95%CI:1.86,2.67))。这些 RR 在 65 岁以下的成年人中更高。唐氏综合征成年人的死亡率比非智障成年人高 6.59 倍(95%CI:4.51,9.62)。
在加拿大安大略省,与 COVID-19 相关的住院率和死亡率在智障成年人中高于其他成年人。这些发现应该为疫苗接种策略提供信息,这些策略通常优先考虑普通人群中的老年人,导致智障人士(他们通常处于较年轻的年龄组)被忽视。